We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Successful Treatment of Enteritis Due to Newly Discovered Gene Mutation

By Michal Siman-Tov
Posted on 07 Dec 2016
Print article
Image: Indirect immunofluorescence on a patient’s intestinal lining shows anti-enterocyte antibodies. Enterocytes are the cells of the intestinal lining (Photo courtesy of the NIH).
Image: Indirect immunofluorescence on a patient’s intestinal lining shows anti-enterocyte antibodies. Enterocytes are the cells of the intestinal lining (Photo courtesy of the NIH).
Researchers report successful treatment of an adult patient with severe chronic autoimmune enteritis by using the drug Vedolizumab to target the effect on T-cell function of a mutation identified in the patient’s CTLA-4 gene. Vedolizumab may also help skin cancer patients with enteritis due to therapy with Ipilimumab.

Over 300 different genetically determined immunodeficiencies have been identified so far. However, as genetic immunodeficiencies rarely occur, they often go unrecognized or are detected too late for effective treatment.

A team led by Mike Recher, professor at University of Basel (Basel, Switzerland) and University Hospital Basel, discovered the CTLA-4 gene mutation and that targeted therapy with Vedolizumab could successfully treat the patient. The patient had a rare mutation in the CTLA-4 protein found on the surface of T-cells. Normally, this protein prevents immune cells from attacking a patient’s own body. However, the mutation caused an autoimmune reaction where T-cells attacked the patient’s intestinal cells, causing chronic inflammation that resulted in the patient suffering from severe diarrhea and weight loss.

Initially, these unusual symptoms had led the cantonal hospital of Graubünden to refer the patient to the special clinic for immunodeficiency at the University Hospital Basel, where immunological investigations suggested a genetically determined dysregulation of the immune system. The new CTLA-4 gene mutation was discovered following subsequent analysis of the entire genome at the University Hospital Zurich. Further investigations showed that the mutation causes reduced CTLA-4 function, which led to increased infiltration of the intestinal mucosa by T-cells and therefore to chronic diarrhea.

Working with the gastroenterology department, the doctors opted for a therapy that uses a new drug from the monoclonal antibody group to prevent the T-cells from penetrating the intestinal mucosa. This drug, Vedolizumab, blocks a specific adhesion molecule on the T-cell surface and thereby inhibits immune cells from binding themselves to receptors present in the intestine, preventing the T-cells from penetrating the blood vessels in the intestinal tissue. This treatment produced the desired outcome: after 3 months, the patient’s chronic diarrhea had stopped completely.

Additionally, this work suggested that CTLA-4 inhibition could be used therapeutically to preventing diarrhea in patients with other diseases, such as when treating melanoma with the drug Ipilimumab, which works similarly to the CTLA-4 mutation in that T-cells are no longer properly inhibited and can more efficiently attack the malignant skin cancer cells. One side effect of Ipilimumab is autoimmune intestinal inflammation – analogous to that caused by the CTLA-4 mutation. It is possible that melanoma patients suffering from severe diarrhea due Ipilimumab will benefit from this new insight, which would open new therapeutic possibilities for Vedolizumab.

This case demonstrates the importance of precise diagnosis of the molecular causes of an illness in enabling targeted, personalized treatment. “In order to expand our knowledge in these areas, doctors in clinics and regional hospitals must be on the alert for unusual disease phenotypes and refer such patients to specialized university hospital clinics for further evaluation,” said Prof. Recher, “We also need clinical university centers that are closely linked to research laboratories.”

The study, by Navarini AA et al, was published online November 28, 2016, in the Journal of Allergy and Clinical Immunology.

Related Links:
University of Basel

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.